Cargando…
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway
INTRODUCTION: Immunocompromised patients with B-cell depletion agents are at risk for persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID-19 patients under B cell depletion therapy, mostly treated with a combined therapy based on intravenous remdesevir (RDV) and ste...
Autores principales: | D’Abramo, Alessandra, Vita, Serena, Maffongelli, Gaetano, Beccacece, Alessia, Agrati, Chiara, Cimini, Eleonora, Colavita, Francesca, Giancola, Maria Letizia, Cavasio, Alessandro, Nicastri, Emanuele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196078/ https://www.ncbi.nlm.nih.gov/pubmed/35711444 http://dx.doi.org/10.3389/fimmu.2022.911339 |
Ejemplares similares
-
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021) -
The first case of meningitis associated with SARS-CoV-2 BA.2 variant infection with persistent viremia
por: D'Abramo, Alessandra, et al.
Publicado: (2022) -
Correction: The unmet need for COVID-19 treatment in immunocompromised patients
por: D’Abramo, Alessandra, et al.
Publicado: (2023) -
The unmet need for COVID-19 treatment in immunocompromised patients
por: Alessandra, D’Abramo, et al.
Publicado: (2022) -
Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature
por: Vita, Serena, et al.
Publicado: (2022)